Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder ...

Alkermes (NASDAQ:ALKS) used its presentation at the J.P. Morgan Healthcare Conference to outline its positioning entering ...

Plymouth Meeting-based Harmony Biosciences expects its narcolepsy drug Wakix to surpass $1 billion in revenue as growth ...

An announcement from Alkermes ( (ALKS) ) is now available.

Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...

Harmony Biosciences expects its narcolepsy treatment Wakix to reach a major sales milestone in 2026, but the Plymouth Meeting ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks to buy according to Wall Street.

The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the ...

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...